Today, the Cystic Fibrosis Foundation announced that it awarded funding to enGene Inc. to develop a customized vehicle to deliver genetic-based therapies, such as gene therapy and gene editing, into the lung cells of people with cystic fibrosis (CF). Delivering genetic-based therapies to the lungs is a key hurdle to developing effective treatments for all people with CF, including individuals with two nonsense and rare mutations.
Site Search
Showing 21 - 26 of 26 results
Press Release
|
Oct. 29, 2020
|
4 min read
The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Press Release
|
Jan. 26, 2021
|
3 min read
Press Release
|
March 19, 2015
|
2 min read
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
Press Release
|
April 16, 2015
|
3 min read
Press Release
|
March 18, 2015
|
3 min read
New Agreement Increases Potential Payments to EPIX by up to $37.7 Million
Press Release
|
April 7, 2008
|
6 min read